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The role of PPARγ in tumorigenesis is controversial. In this article, we review and analyze literature from the past decade that
highlights the potential proneoplastic activity of PPARγ. We discuss the following ﬁve aspects of the nuclear hormone receptor
and its agonists: (1) relative expression of PPARγ in human tumor versus normal tissues; (2) receptor-dependent proneoplastic
eﬀects; (3) impact of PPARγ and its agonists on tumors in animal models; (4) clinical trials of thiazolidinediones (TZDs) in
human malignancies; (5) TZDs as chemopreventive agents in epidemiology studies. The focus is placed on the most relevant in
vivo animal models and human data. In vitro cell line studies are included only when the eﬀects are shown to be dependent on the
PPARγ receptor.
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1. INTRODUCTION
PPARγ is a nuclear hormone receptor that requires ligand
binding for activation. In 1995, it was discovered that PPARγ
is the molecular target of thiazolidinediones (TZDs, [1]),
a class of synthetic compounds that are eﬀective for the
treatment of type 2 diabetes. This discovery spurred great
interest in these agents, as well as in the receptor. Besides
its function as an insulin sensitizer in diabetes, PPARγ
was found to have a variety of roles in immunoregulation,
atherosclerosis, angiogenesis, and tumorigenesis.
With regards to carcinogenesis, debate continues as to
whether PPARγ is pro- or antineoplastic, despite very active
research over the past few years. At the cellular level, PPARγ
was found to be involved in cancer cell survival/apoptosis,
proliferation, and diﬀerentiation. While the apoptotic func-
tions of PPARγ and its agonists are addressed by others in
this special issue, we will conduct a critical review of the
literature that suggests that PPARγ has a prosurvival activity.
The review is mainly focused on data derived from in vivo
models and/or human studies. In vitro cell line-based studies
areincludedonlywhentheeﬀectsareshowntobedependent
on the PPARγ receptor.
One important lesson learned from the past several years
of research is that eﬀects observed with agonists of PPARγ
are not necessarily intrinsic eﬀects of the nuclear hormone
receptor. In tumor cell survival, the proapoptotic activities of
PPARγ agonistsinvarioustumorsactthroughbothreceptor-
dependent and receptor-independent mechanisms. When
reviewing the literature, we advise that the readers carefully
consider the following to distinguish drugs or TZDs versus
receptor eﬀects: (1) are high or low doses used in the studies?
High or low doses should be deﬁned with respect to EC50
of glitazones in the PPARγ transactivation assays (Table 1)
or plasma concentrations that can be reached in humans
(Table 2). Eﬀects observed with high concentrations may
not be relevant due to toxicities of certain TZDs, such as
hepatotoxicity of troglitazone and potential cardiotoxicity of
rosiglitazone (see below). (2) Are multiple pharmacological
agents used? If a pharmacological approach is the only
one used, claims of a receptor-dependent eﬀect require
demonstrationwithagonistsofdiﬀerentchemicalstructures,
such as TZDs, tyrosine analogues, 15-Deoxy-Δ12,14-PGJ2
(15d-PGJ2), and so forth. Beware that 15d-PGJ2 possesses
many PPARγ-independent activities, including inhibition of
the NFκB pathway, that are known to have prosurvival and
anti-inﬂammatory properties, as well as other eﬀects [2–4].
(3)Areanyantagonistsincludedinthestudy?Doantagonists
GW9662 or T0070907 block or reverse the observed eﬀects?
(4) Are there any experiments in the study utilizing a genetic2 PPAR Research
approach to conﬁrm the pharmacological ﬁndings? Does the
study involve cell lines or primary cells that contain or lack
PPARγ,preferablyinthesamegeneticbackground?Forthose
cell lines with endogenous PPARγ, is the siRNA, shRNA or
dominant negative form of PPARγ used to reduce the levels
ofthereceptor?Arespeciﬁceﬀectsofthereceptordiminished
by such reduction? For readers’ convenience, these questions
are summarized in Table 3.
2. EXPRESSION OF PPARγ IN HUMAN TUMOR
VERSUS NORMAL TISSUES
It is generally believed that expression of a gene in a
particular tissue suggests that the activity of the encoded
protein is required for certain cellular functions of that
tissue. In so far as cancers are concerned, the general rule is
that oncogenes are overexpressed due to dysregulation, and
tumor suppressor genes are underexpressed or absent due
to mutations or deletions. In order to clarify the roles of
the PPARγ receptor, it would be informative to review the
expression levels of PPARγ in tumors with respect to their
normal tissue counterparts. In this article, expression data
from tumor cell lines are not included.
A review of the current literature on human cancers
showed that expression levels of PPARγ mRNA and protein
are generally higher in neoplastic tissues than their normal
counterparts (summarized in Table 4). The most convincing
data came from a large study of prostate cancer that included
156patientswithprostatecancer(PC),15withlessaggressive
prostatic intraepithelial neoplasia (PIN), 20 with benign
prostatic hyperplasia, and 12 normal prostate tissues. In this
study, a high level of PPARγ expression, by immunohisto-
chemistry, is observed in PC and PIN cases in comparison
to low or no expression in the benign hyperplasia and
normal tissues. The results were conﬁrmed at the mRNA
level with RT-PCR on a few cases from each category of
the malignant and benign conditions [13]. A large study
of 126 renal cell carcinomas also showed signiﬁcantly more
extensive and intensive PPARγ staining in tumor epithelium
compared to the average staining levels seen in 20 normal
tissues [14]. Similarly, in 22 patients with nonsmall cell
lung carcinoma, higher levels of PPARγ are expressed in
tumor cells than in the surrounding normal tissue, as
determined by immunohistochemical staining. In addition,
higher expression levels in tumor cells are conﬁrmed by
Western blotting hybridization, using homogenized tissue
samples [15]. In hepatocellular carcinoma, immunostaining
also demonstrates that PPARγ is overexpressed in all of 20
c a r c i n o m at i s s u e sb u tn o ti nn o r m a lh e p a t o c y t e s[ 16]. For
squamous cell carcinoma, 20 cases of primary tumor and six
cases of lymph node metastasis were demonstrated to have
increased PPARγ protein expression compared to normal
tongue tissue [17]. Inﬁltrating adenocarcinoma of the breast
also expresses higher nuclear staining of PPARγ compared
to normal ductal epithelial cells by immunohistochemical
analysis. However, only one of the three cases was shown
[18]. For papillary thyroid carcinoma, six patients were
studied to determine PPARγ mRNA expression using reverse
transcription PCR. The message was found in three of six
tumor tissues while the corresponding normal tissues do not
express PPARγ [19].
Follicular thyroid carcinoma, a less common histological
subtypeofthyroidcancer,ischaracterizedbyachromosomal
translocation t(2;3) that results in a fusion between paired
box gene 8 on chromosome 2 and PPARγ on chromosome
3 (PAX8-PPARγ). The fusion protein was initially thought
to function as a dominant-negative inhibitor of the wild-
type PPARγ protein [28]. However, a recent microarray
study revealed that (1) PPARγ transcript levels in all seven
cases of PAX8-PPARγ-containing follicular carcinomas are
more than 10-fold higher than normal thyroid tissues, as
determined by both microarray and quantitative RT-PCR
analyses; (2) the expression proﬁle of the fusion-positive
follicular carcinomas shows induction of genes that are
involved in fatty acid, amino acid, and glucose metabolic
pathways. Interestingly, many of the upregulated genes are
known transcriptional targets of the wild-type receptor,
suggesting that the PAX8-PPARγ fusion protein functions
similarly to wild-type PPARγ, rather than antagonizing its
activity. (3) Using cell lines transfected with PPARγ or
the fusion protein, it is shown that expression of some
genes, including angiogenic factors PGF and ANGPTL4, is
speciﬁcally upregulated by the fusion protein, particularly
in the absence of ligand, indicating that the fusion protein
is constitutively active. Taken together, these experimental
data suggest that the translocation enhances the function
of PPARγ in a way that contributes to the development or
progression of follicular carcinoma of the thyroid [29].
Upregulation of PPARγ has been demonstrated during
tumor progression. Mueller et al. have found signiﬁcant
PPARγ staining in six cases of metastatic breast adeno-
carcinoma. In cell lines established from the primary and
metastatic tumors of one of these patients, signiﬁcantly
higher amounts of PPARγ transcript are shown in the cell
line derived from the metastatic tumor [20]. In ovarian
cancer, intensity and location of PPARγ immunostaining
were examined in 28 carcinoma cases along with 28 normal,
benign or borderline cases. Twenty six of 28 carcinomas
showed strongly positive PPARγ staining compared to 2
weak-staining cases in the control group. Moreover, it is
noted that PPARγ staining was predominantly nuclear in
grade 2 or 3 tumors, as compared to a predominantly
cytoplasmic staining pattern in grade 1 tumors [21]. Similar
ﬁndings were made in transitional cell carcinoma of urinary
bladder. Whereas no signiﬁcant PPARγ immunoreactivity
was observed in 20 normal tissues, elevated PPARγ was
found in 168 tumors. Furthermore, the intensity of staining
increased as the histological grade increased from G1 to G3
and the tumor stage increased from early (pT1 or lower) to
advanced (stage 2 or higher) [22].
Arecentlargestudyof129 casesofpancreatic ductalade-
nocarcinoma convincingly showed by array-based gene pro-
ﬁling that expression of PPARγ in the tumor cells is ∼7f o l d
higher than that in the normal ductal epithelia. This ﬁnding
was conﬁrmed with immunohistochemical analysis of the
tissue sections. Normal ductal epithelia showed insigniﬁcant
staining for PPARγ. An early lesion, intraepithelial neoplasia
showed occasional PPARγ expression whereas more thanY. Lynn Wang and Q. Miao 3
Table 1: EC50 of common PPARγ agonists in transactivation assays.
Agonists Constructsused for transactivation EC50 (μM) References
Ciglitazone mPPARγ1L B D (a)-GAL4 DBD(b) 3[ 5]
Pioglitazone
Wild-type mPPARγ10 . 4 [1]
Wild-type mPPARγ20 . 4
mPPARγ1(c) LBD-GAL4 DBD 0.55 [6]
hPPARγ1(d) LBD-GAL4 DBD 0.58
Rosiglitazone
Wild-type mPPARγ10 . 0 3 [1]
Wild-type mPPARγ20 . 1
mPPARγ1 LBD-GAL4 DBD 0.076 [6]
hPPARγ1 LBD-GAL4 DBD 0.043
Troglitazone mPPARγ1 LBD-GAL4 DBD 0.78 [6]
hPPARγ1 LBD-GAL4 DBD 0.55
15d-PGJ2
Wild-type mPPARγ1 2[ 7]
mPPARγ1 LBD-GAL4 DBD
(a) LBD, ligand binding domain.
(b) DBD, DNA binding domain.
(c) mPPARγ1, mouse PPARγ1.
(d) hPPARγ1, human PPARγ1.
Table 2: Peak plasma concentrations of PPARγ agonists.
Agonists Cmax
(a) (μM) References
Ciglitazone 15∼30(b) [8]
Pioglitazone 0.2∼2.5 [9]
Rosiglitazone 0.2∼1.7 Avandia Prescribing
Information(c)
Troglitazone 0.7∼8.8 [10]
15d-PGJ2
Low nanomolar to
picomolar range(d)
[11]
[12]
(a)Cmax, the maximum or peak plasma concentration in human unless
otherwise indicated.
(b)That in dog plasma.
(c)From http://us.gsk.com/products/assets/us avandia.pdf.
(d)Physiological concentrations in cerebrospinal ﬂuid, urine, and the
interior of adipocytes.
Table 3: Points to be considered to discern drugs/TZDs versus
receptor eﬀects.
(1) Are high or low doses of drugs used in the studies with
respect to their Kd values for PPARγ, or plasma concentrations?
(2) Are multiple pharmacological agents of diﬀerent chemical
classes used?
(3) Are any antagonists included in the study?
(4) Are any genetic approaches used to conﬁrm the pharmaco-
logical ﬁndings?
70% of invasive pancreatic carcinoma demonstrated weak
to strong expression. Statistical analysis indeed revealed that
expression of PPARγ correlates with high tumor stage and
higher tumor histological grade. More strikingly, expression
of PPARγ in pancreatic cancer is shown, by multivariant
survival analysis, to be a signiﬁcant prognostic indicator for
shortened patient survival [23].
In parallel to the above literature, levels of PPARγ mRNA
found in several well- or poorly-diﬀerentiated colorectal
adenocarcinomas, were similar to normal tissues [24].
Another group also found that the PPARγ immunostain-
ing in well-, moderately-, or poorly-diﬀerentiated gastric
adenocarcinomas is comparable to that in noncancerous
tissue adjacent to the tumor [25]. In liposarcomas, PPARγ
transcript levels are similar to that of the adipose tissue [26].
In adrenal glands, there is, again, no signiﬁcant diﬀerence in
mRNA expression among cases of carcinoma, adenoma, and
normal tissues [27]. Notably, at the time of composition of
this manuscript, we have not yet found any reports stating
that PPARγ expression is downregulated or absent in human
tumor versus normal tissues (Table 4).
Thenext questioniswhetheror not thePPARγ expressed
in tumor tissues is functional. Are ligands of PPARγ present
in the tumor tissues? A thorough and up to date literature
search yielded few results. The English abstract of a study
published in a foreign language stated that there was no
signiﬁcant diﬀerence in 15d-PGJ2 concentration between
gastric cancer tissues and controls [30]. An earlier study
showed that 15d-PGJ2 promotes the proliferation of HCA-
7, a cyclooxygenase 2 (COX-2)-containing colon cancer cell
line at nanomolar concentrations. Further characterization
by HPLC and mass spectrometry identiﬁed PGJ2,ac h e m i c a l
precursor of 15d-PGJ2 in the culture medium of HCA-7 cells
[31]. COX-2 is a key enzyme in the biochemical pathway
that leads tothe formationofcyclopentenone prostaglandins
including 15d-PGJ2. Overexpression of COX-2 has been
documented in many cancer types and contributes to tumor
growth[32].Overall,these fewand somewhatcircumstantial
evidences suggest that 15d-PGJ2 might be present in the
tumor tissues.4 PPAR Research
Table 4: PPARγ expression in human tumor versus normal tissues.
Tumor versus normal tissue No. of cases References
Overexpression
Prostate cancer/prostatic intraepithelial neoplasia 156/15 [13]
Renal cell carcinoma 126 [14]
Nonsmall-cell lung carcinoma 22 [15]
Hepatocellular carcinoma/lymph node metastasis 20/6 [16]
Squamous cell carcinoma 20 [17]
Metastatic breast adenocarcinoma 6 [20]
Inﬁltrating ductal breast adenocarcinoma 3 [18]
Papillary thyroid carcinoma 6(a) [19]
Increased expression during tumor progression
Breast adenocarcinoma 1(b) [20]
Ovarian carcinoma 28 versus 28(c) [21]
Urinary bladder carcinoma 100 versus 70(d) [22]
Pancreatic ductal adenocarcinoma 45 versus 84(e) [23]
Similar expression
Colorectal adenocarcinoma 11 [24]
Gastric adenocarcinoma 12 [25]
Liposarcoma 13 [26]
Adrenocortical tumors 32 [27]
(a) Of the six papillary carcinoma tissues, three expressed PPARγ mRNA.
(b) The primary and metastatic breast cancer cell lines were derived from a single patient.
(c) Normal, benign, or borderline versus malignant tumors (grades 1, 2, and 3).
(d) Lower (≤pT1) versus higher (≥pT2) tumor stages.
(e) Lower (pT1 & pT2) versus higher (pT3 & pT4) tumor stages.
Does PPARγ lose or gain abnormal functions through
mutations other than PAX8-PPARγ translocation? A large
survey of human tumor samples and cancer cell lines does
not support sucha notion. The exon 3and5 mutations, once
reported in sporadic colon cancers [33], were not present in
nearly 400 cell lines and primary tumor samples including
lung, breast, prostate, colon cancers, and leukemias [34].
Takentogether,severallinesofevidenceregardingPPARγ
expression suggest a positive contributive role of the recep-
tor in the development, maintenance, or progression of
human malignancies: (1) PPARγ is overexpressed in the vast
majority of cancers. (2) In several types of cancer, PPARγ
expression is further increased during tumor progression.
(3) The oncogenic fusion PAX8-PPARγ results in PPARγ
overexpression and upregulation of a similar proﬁle of tran-
scriptional targets as the wild-type protein. (4) Expression
of PPARγ in pancreatic cancer is associated with shorter
survival.
3. RECEPTOR-DEPENDENT PRONEOPLASTIC
EFFECTS OF PPARγ
Is there also cellular-level evidence suggesting that PPARγ
promotes tumors? Most studies, especially those employing
high doses of TZDs, suggest that PPARγ agonists have anti-
tumor activities through inhibition of cell proliferation or
induction of apoptosis or diﬀerentiation. However, receptor-
independent pathways are involved in most of the cases
(reviewed elsewhere in this special issue). Then what does
the receptor by itself do in tumors?
Schaefer et al. showed that inhibition of PPARγ induces
apoptosis of hepatocellular carcinoma cells (HCCs) by
preventing their adhesion to the extracellular matrix, sug-
gesting that the activity of PPARγ is required for HCC
c e l l st oa d h e r ea n ds u r v i v e[ 16]. In that study, those
particular eﬀects were shown to be receptor-dependent.
Loss of cell adhesion requires almost complete loss of
PPARγ activity achieved by either PPARγ-targeting siRNA
or PPARγ inhibitor T0070907. In addition, T0070907 causes
cell death at concentrations far lower than those needed for
PPARγ agonists rosiglitazone and troglitazone. Together, the
data suggest that PPARγ functions to promote tumor cell
adhesion and survival in HCC cells. In line with this notion,
the promoter region of hepatocyte growth factor contains a
functional PPAR response element (PPRE) that mediates its
transcriptional upregulation by PPARγ. The growth factor
plays an essential role in liver growth during embryonic
development, as well as in maintenance and renewal of
cells in various organs including liver, lung, and kidney, in
adulthood [35].
Our laboratory studied human anaplastic large T-cell
lymphomas, a common form of large cell lymphoma
in the pediatric population. We ﬁrst demonstrated with
immunohistochemical staining that PPARγ is expressed in
the malignant cells of the lymphoma tissues [36]. We then
tested the eﬀect of PPARγ activation in cell lines established
from patients with this lymphoma. A pair of cell lines,Y. Lynn Wang and Q. Miao 5
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Figure 1: Schematic diagram showing how PPARγ i n c r e a s e sc e l ls u r v i v a li ng r o w t hf a c t o r / n u t r i e n t - d e p r i v e dc e l l s . Growth factor/nutrient
withdrawal induces ROS production. In the absence of PPARγ activation, increased levels of ROS inhibit mitochondrial electron transport,
leading to mitochondrial depolarization, caspase activation, and cell death. When PPARγ is activated, the increase in ROS is attenuated by
the receptor through transcriptional upregulation of cell type speciﬁc antioxidant factors, such as catalase, Cu/Zn-SOD (SOD1), Mn-SOD
(SOD2), or UCP2. The transcriptional upregulation of these genes by PPARγ may or may not be direct (shown to be direct in the diagram
for simplicity).
Karpas 299 and SUP-M2 that, respectively, contain and lack
endogenous PPARγ were selected to address the receptor-
dependency issue. Additionally, only low ligand concentra-
tions were used, following initial dose titration, to minimize
any oﬀ-target eﬀects. Using this system, we have found that
low doses of PPARγ agonists do not aﬀect cell survival
under normal conditions. When cell death was induced by
nutrient deprivation through serum withdrawal, activation
of the receptor with low doses of rosiglitazone (0.5–2μM)
attenuated cell death, as compared to drug vehicle-treated
cells. This result was reproducible with low doses of GW7845
(0.5–2μM) and 15d-PGJ2(0.5–1μM). The eﬀect occurred
only in PPARγ-containing Karpas 299 cells but not in
PPARγ-lacking SUP-M2 cells. Moreover, reducing PPARγ
in Karpas 299 cells with siRNA diminished the prosurvival
eﬀect of the receptor. Furthermore, we showed that the
prosurvival eﬀect is mediated through PPARγ-dependent
cellular metabolic changes, including increased cellular ATP
levels, stabilized mitochondrial membrane potential, and
reduced reactive oxygen species (ROS) production that each
favor cell survival. PPARγ does so through coordinated
regulation of the expression of ROS metabolic enzymes,
including the p67 subunit of NADPH oxidase, uncoupling
protein 2 (UCP2), and manganese superoxide dismutase
(Mn-SOD) at both mRNA and protein levels that lead to
ROS limitation. Lastly, we showed that stable transfection of
PPARγ into SUP-M2 cells not only improved cell survival,
but also suppressed ROS accumulation during serum starva-
tion. These genetic manipulations have provided deﬁnitive
evidence that PPARγ promotes lymphoma cell survival
under conditions of nutrient deprivation.
Our group has also made similar ﬁndings in a murine
cellular model [37, 38]. FL5.12 is a murine lymphocytic
cell line that requires interleukin-3 (IL-3) for survival and
proliferation. This cell line has been extensively used to
characterize tumor cell metabolism [39]. FL5.12 cells express
little PPARγ, but are killed by high concentrations of PPARγ
agonists, 15d-PGJ2 (≥10μM) and ciglitazone (≥80μM).
In an FL5.12 cell line stably-transfected with PPARγ,l o w
doses of PPARγ agonist do not aﬀect cell viability under
normal conditions. However, when cells are induced to die
by IL-3 withdrawal, low doses of ciglitazone (10μM) and
rosiglitazone (0.05–2μM) improved survival in only PPARγ-
containing cells. Improved cell survival is also accompanied
bystabilizedmitochondriaandreducedROS.Moreover,ATP
production is required for PPARγ to exert its prosurvival
eﬀect. In this system, expression of a diﬀerent panel of
ROS metabolic enzymes including catalase, and Cu/Zn-SOD
are involved in reduction of the cellular levels of ROS.
Functional PPRE sequences were shown to be present in
the promoter regions of these two genes, suggesting that the
upregulation of their expression could be directly regulated
by PPARγ [40–42]. Taken together, data from both human
and murine cell line studies suggest that PPARγ promotes6 PPAR Research
tumor cell survival under conditions of nutrient/growth
factor deprivation, and that the eﬀect is not limited to a
particularsystem.ThemechanismbywhichPPARγ increases
cell survival is diagrammed in Figure 1 (Also see below).
In support of the prosurvival activity of PPARγ in T-cell
malignancies, Ferreira-Silva et al. very recently showed that
RNAi-mediated silencing of PPARγ in Jurkat T-cells caused
increased DNA fragmentation and apoptosis as well as G2/M
cell cycle arrest, arguing that the receptor, proper, promotes
the viability of the tumor cells [43].
In parallel to these ﬁndings in tumors, the prosurvival
activity of PPARγ has been well documented in certain
nonneoplastic pathological conditions, especially ischemia-
reperfusion injury in nutrient-sensitive tissues such as brain,
heart and kidney [44–51]. Irreversible damage that results
from prolonged ischemia causes stroke, and myocardial
and kidney infarction. At the cellular level, cell death
occurs as a result of nutrient deprivation and inﬂamma-
tory responses that involve the actions of proinﬂammatory
cytokines, chemokines and transcriptional factors. In addi-
tion, increased production of ROS plays an important role in
causing damage to macromolecules and eventual cell death
[52]. A recent study using a rat model of cerebral focal
ischemia has shown that expression of PPARγ mRNA and
protein is upregulated in the areas adjacent to infarct caused
by middle cerebral artery occlusion [46]. Administration of
glitazones prior to, at the time of, or shortly after ischemia
induction causes an increase in DNA binding of the receptor.
This is accompanied by a decrease in the expression of a
number of inﬂammatory genes, along with an increase in
the expression of antioxidant enzymes including catalaseand
Cu/Zn-SOD [44–47]. Consequently, these changes lead to
limited cell demise, which eventually results in signiﬁcantly
reduced infarct size. This process apparently works through
aP P A R γ-dependent mechanism, as GW9662 can block these
eﬀects of TZDs in animals [47]. Another PPARγ antagonist,
T0070907, even increases the infarction size, both in the
presence and absence of PPARγ ligands [46].
In light of both these ﬁndings and the overexpression
of PPARγ in many cancers, it is reasonable to hypothesize
that the function of PPARγ in cancer is to confer a survival
advantageuponthemalignantcells,allowingthemtosurvive
in an adverse environment. As a result of fast growth, the
center of a three dimensional tumor mass is often deprived
ofoxygen,growthfactors,glucose,andothernutrientsdueto
excessive demand and insuﬃcient vascularization. However,
cancer cells possess remarkable tolerance and are able to
survive despite the adverse conditions [53, 54]. Besides
increasing angiogenesis, increasing PPARγ might be another
mechanism that allows tumor cells to enhance their survival
under these unfavorable conditions (Figure 1).
4. IMPACT OF PPARγ AND ITS AGONISTS ON
ANIMAL TUMOR MODELS
Animal models were employed to examine the role of PPARγ
in tumors. These systems can be categorized by how the
tumor models are generated and by how the dose/activity
of PPARγ is altered. With respect to the former, tumors
can be generated with xenografts, carcinogens, or genetic
manipulations. Watch for spontaneous tumor formation in
certainPPARγ geneticbackgroundshasalsobeenconducted.
With respect to the dose/activity of PPARγ,i tc a nb e
altered using PPARγ agonists including TZDs or GW7845,
or genetic manipulations including hemizygosity or tissue-
speciﬁc overexpression or deletion of PPARγ. Results diﬀer
drastically between diﬀerent model systems, even for the
same types of cancer (Tables 5 and 6). This review focuses
on models that are more relevant to human cancers. As
such,animalstudiesinvolvingTZDtreatmentofxenografted
tumors are not discussed here.
4.1. Coloncancer
Apc+/Min mice possess a nonsense mutation in one copy of
the adenomatous polyposis coli (APC) gene which truncates
the protein at amino acid 850. Loss-of-function mutations in
the APC gene are common in human familial adenomatous
polyposis andcanbe found insporadic coloncancersas well.
Using this model, which is highly relevant to human colon
cancers, one study showed an increase in tumor number
and size, as well as worse histological grade in mice treated
with troglitazone or rosiglitazone. This is associated with a
rosiglitazone-induced increase in the β-catenin protein level
in the colon tissues [55]. Another study [56], which also
used Apc+/Min mice, reported an increase in the number
of colon polyps in troglitazone-treated mice, but reported
no signiﬁcant diﬀerence in tumor size or histology, which
may be related to the shorter TZD treatments used in this
study (5 weeks as compared to 8 weeks in the ﬁrst study).
Similar ﬁndings were made in Apc+/1638N : Mlh1+/− double
mutant mice. In these mice, one copy of the APC gene
is truncated at amino acid position 1638 and one of the
two alleles of the DNA repair enzyme Mlh1 is absent. In
the double mutant mice, troglitazone treatment signiﬁcantly
increased the number of mice that developed large intestine
tumors [58]. In contrast to these reports, another study
used Apc+/1638N mice crossed with hemizygous PPARγ mice.
Becausehomozygousdeletion ofPPARγ is embryonic-lethal,
studiesexaminingthedoseeﬀectofthegeneemployedeither
ah e m i z y g o u sPparγ+/− mouse strain or a conditional knock-
out strategy. No diﬀerences in survival, number of colonic
tumorsorβ-cateninexpressionlevelswereobservedbetween
mice of Apc+/1638N :P p a r γ+/− and Apc+/1638N :P p a r γ+/+
littermates [57]. Therefore, in colon cancer induced by APC
mutations, it appears that activation of PPARγ by TZDs
promotes tumor formation, while reduction of PPARγ gene
dosage has little eﬀect on tumor formation.
In stark contrast to the APC genetic tumor models,
carcinogen-generated colon cancer models seem to yield
opposite results. In the study that evaluated PPARγ hap-
loinsuﬃciencyinanApc+/1638N background,theinvestigators
also determined the eﬀect of Pparγ+/− in azoxymethane-
mediated colon cancer. Compared to the Pparγ+/+ mice, a
greater number of haploinsuﬃcient mice developed tumors
in the colon. The tumor-bearing Pparγ+/− mice also had
a greater number of tumors in them that led to signif-
icantly decreased survival. In another study, mice withY. Lynn Wang and Q. Miao 7
Table 5: PPARγ and agonists in animal models (diﬀerentially shaded according to methods of tumor induction).
Un-shaded: Genetic tumor models
Light grey-shaded: Carcinogen-induced tumor models
Dark grey-shaded: Spontaneous tumor formation
Cancer type Tumor induction PPARγ activation
(↑)/reduction(↓) Tumorresponse PPARγ’s eﬀect References
Colon Apc+/Min ↑ Troglitazone,
Rosiglitazone
Increased incidence and
size of tumor Promoting [55, 56]
Colon Apc+/1683N ↓ Pparγ+/− No response No eﬀect [57]
Colon Apc+/1683N :M l h 1
+/− ↑ Troglitazone Increased tumor incidence Promoting [58]
Colon Azoxymethane ↓ Pparγ+/− Increased tumor incidence,
number, shortened survival Suppressing [57]
Colon Azoxymethane
↑ Troglitazone,
pioglitazone, or
rosiglitazone
Decreased tumor
incidence, number, and size Suppressing [59]
Colon Spontaneous
↑ Troglitazone (5
weeks) No response No eﬀect [56]
Colon Spontaneous
↑ Troglitazone (6
months) Increased tumor incidence Promoting [58]
Mammary glands Polyoma virus middle
T antigen
↑ Tissue speciﬁc
constitutive activation
of PPARγ
Promoted tumor
development Promoting [60]
Mammary glands Polyoma virus middle
T antigen
↓ Pparγ+/− No response No eﬀect [60]
Mammary glands MNU(a) ↑ GW7845 Decreased tumor incidence,
number, and total weight Suppressing [61]
Mammary,ovarian,
skin DMBA(b) ↓ Pparγ+/− Increased tumor incidence
and number, worse survival Suppressing [62]
Mammary glands Spontaneous
↓ Tissue-speciﬁc
PPARγ deletion No response No eﬀect [63]
Mammary glands Spontaneous ↓ Pparγ+/− No response No eﬀect [62]
Prostate SV40 T antigen ↓ Pparγ+/− No response No eﬀect [64]
Thyroid DN-TRβ(c) ↓ Pparγ+/− Increased metastases,
shortened survival Suppressing [65]
Thyroid DN-TRβ ↑ Rosiglitazone Reduced tumor growth,
delayed progression Suppressing [65]
Gastric MNU ↓ Pparγ+/− Increased tumor incidence,
shortened survival Suppressing [66]
Gastric MNU ↑ Troglitazone Decreased tumor incidence Suppressing [66]
Lung Urethan
↑ Tissue-speciﬁc
PPARγ overexpression Decreased tumor incidence Suppressing [67]
(a) MNU, N-methyl-N-nitrosourea.
(b) DMBA, 7,12-dimethylbenzanthracene.
(c) DN-TRβ, dominant-negative mutant of thyroid hormone receptor β.
azoxymethane-mediated colon cancer were treated with
troglitazone, pioglitazone, or rosiglitazone. This resulted in
reduced incidence, number, and size of colorectal tumor
[59]. Taken together, these data suggest that PPARγ suppress
azoxymethane-induced colon carcinogenesis.
What would happen in normal mice? Spontaneous
colon tumor development was evaluated in normal mice
administered with troglitazone [58]. All nine mice fed with
troglitazone developed tumors in the large intestine, in
contrast to none of the 10 mice in the control group. An
earlier study did not ﬁnd any tumors in 17 troglitazone-fed
normal mice, possibly due to the short duration of feeding (5
weeks in [56] versus 6 months in [58]).
4.2. Mammaryglandtumors
Themammaryglandtumorisanotherrelativelywell-studied
tumor in animals. Similar to colon carcinogenesis, data on
PPARγ’s role in mammary gland carcinogensis suggest a
wide range of eﬀect depending on the tumor models (Tables
5 and 6). Some studies indicate no eﬀect, while others
suggest that it has a tumor promoting role, while others yet8 PPAR Research
Table 6: PPARγ and agonists in animal models (diﬀerentially shaded according to methods of PPARγ manipulation).
Un-shaded: Activation of PPARγ by pharmacological agonists
Light grey-shaded: Reduction of PPARγ gene dosage
Dark grey-shaded: Tissue speciﬁc PPARγ overexpression
Cancer type Tumor induction PPARγ activation
(↑)/reduction(↓) Tumorresponse PPARγ’s eﬀect References
Colon APC
Min/+ ↑ Troglitazone,
Rosiglitazone
Increased incidence and
size of tumor Promoting [55, 56]
Colon Apc+/1638N ↓ Pparγ+/− No response No eﬀect [57]
Colon Apc+/1638N :M l h 1
+/− ↑ Troglitazone Increased tumor incidence Promoting [58]
Colon Azoxymethane ↓ Pparγ+/− Increased tumor incidence,
number, shortened survival Suppressing [57]
Colon Azoxymethane
↑ Troglitazone,
pioglitazone, or
rosiglitazone
Decreased tumor
incidence, number, and size Suppressing [59]
Colon Spontaneous
↑ Troglitazone (5
weeks) No response No eﬀect [56]
Colon Spontaneous
↑ Troglitazone (6
months) Increased tumor incidence Promoting [58]
Mammary glands Polyoma virus middle
T antigen
↑ Tissue speciﬁc
constitutive activation
of PPARγ
Promoted tumor
development Promoting [60]
Mammary glands Polyoma virus middle
T antigen
↓ Pparγ+/− No response No eﬀect [60]
Mammary glands MNU(a) ↑ GW7845 Decreased tumor incidence,
number, and total weight Suppressing [61]
Mammary,ovarian,
skin DMBA(b) ↓ Pparγ+/− Increased tumor incidence
and number, worse survival Suppressing [62]
Mammary glands Spontaneous
↓ Tissue-speciﬁc
PPARγ deletion No response No eﬀect [63]
Mammary glands Spontaneous ↓ Pparγ+/− No response No eﬀect [62]
Prostate SV40 T antigen ↓ Pparγ+/− No response No eﬀect [64]
Thyroid DN-TRβ(c) ↓ Pparγ+/− Increased metastases,
shortened survival Suppressing [65]
Thyroid DN-TRβ ↑ Rosiglitazone Reduced tumor growth,
delayed progression Suppressing [65]
Gastric MNU ↓ Pparγ+/− Increased tumor incidence,
shortened survival Suppressing [66]
Gastric MNU ↑ Troglitazone Decreased tumor incidence Suppressing [66]
Lung Urethan
↑ Tissue-speciﬁc
PPARγ1 overexpression Decreased tumor incidence Suppressing [67]
(a)MNU, N-methyl-N-nitrosourea.
(b)DMBA, 7,12-dimethylbenzanthracene.
(c)DN-TRβ, dominant-negative mutant of thyroid hormone receptor β.
suggest a tumor suppressing role. A murine genetic model
supports a tumor-promoting role [60]. In this model, the
mammary gland tumor is induced by mammary gland-
speciﬁc expression of polyoma middle T antigen (MMTV-
PyV). Mammary gland speciﬁc constitutive expression of
PPARγ (MMTV-VpPPARγ) did not yield tumor develop-
ment. However, when crossed with the MMTV-PyV mice,
thedoublemutantprogenydevelopedmoremammarygland
tumors sooner than MMTV-PyV mice. The increased tumor
burden eventually led to shorter survival. Interestingly,
hemizygosity of PPARγ in the MMTV-PyV background
did not change the time course of tumor development.
Exacerbation of tumor formation by PPARγ was ascribed
to increased Wnt-β catenin signaling as demonstrated by
zebraﬁsh developmental models.
In contrast to this genetic model, chemically induced
mammary gland tumors were inhibited by PPARγ agonists.
BothTZDsandGW7845,atyrosineanalog,havebeenshown
to exhibit antitumor eﬀects. An early study using nitro-
somethylurea (MNU) to induce mammary carcinogenesis
showed that GW7845 reduced the incidence, number of
tumors per animal, and average weight of tumor at autopsyY. Lynn Wang and Q. Miao 9
following a two-month administration of the drug to rats
[61]. In 7,12-dimethylbenzanthracene (DMBA)-mediated
mouse carcinogenesis model, the animals develop multiple
types of tumor, including mammary ductal papilloma and
adenocarcinoma. Incidence of mammary gland tumor was
signiﬁcantly higher in Pparγ+/− mice than in Pparγ+/+ mice.
The hemizygous mice also had increased number of tumors
and a lower survival rate [62].
Spontaneous tumor formation was also examined in
Pparγ+/− mice. Dose reduction of PPARγ does not make ani-
mals prone to increased carcinogenesis [62]. In concordance
with this ﬁnding, the speciﬁc deletion of PPARγ in mouse
mammary epithelia failed to induce mammary tumors in 20
mice observed for 12 months [63].
4.3. Othercancers
In a murine prostate cancer model, generated using tissue-
speciﬁc SV40 T antigen, reduced Pparγ+/− had no eﬀects
on tumor incidence, latency, size, histopathology, or disease
progression [64]. However, in a murine follicular thyroid
cancer model containing a dominant-negative mutant form
of thyroid hormone receptor β (TRβPV/PV), loss of one
PPARγ allele led to increased weight of tumor-bearing
thyroid gland, increased lung metastasis, and shortened
survival. In addition, rosiglitazone treatment of TRβPV/PV
mice reduced thyroid weight, and tumor progression [65],
suggesting a tumor-suppressing role for PPARγ. Lastly, in
gastric carcinoma, induced with MNU, PPARγ haploinsuf-
ﬁcient mice had increased tumor incidence and shorter
survival. Troglitazone treatment signiﬁcantly reduced tumor
incidence in mice with wild-type PPARγ background [66].
In summary, results from animal studies regarding
the role of PPARγ are conﬂicting and diﬃcult to assess.
For the purpose of clariﬁcation, we attempted to analyze
the published data according to the cancer types, tumor
induction models, PPARγ activation/reduction methods,
and tumor characteristics (Tables 5 and 6). Our extensive
analysis revealed no clear pattern. However, some trends
have been noted: (1) in multiple types of carcinogen-
induced tumor (Table 5, light grey shaded rows), PPARγ
seems to have a tumor-suppressing function. This appears
to be independent of how PPARγ is activated or reduced,
whereas in genetic tumor models (Table 5, un-shaded rows),
the receptor exhibited all possible diﬀerent eﬀects. As to
spontaneous tumors (Table 5, dark grey shaded rows), long-
term use of troglitazone increased tumor formation, whereas
PPARγ reduction had no eﬀect; (2) a reduction of PPARγ
dose by itself (Table 6, light grey shaded rows) is insuﬃcient
to induce spontaneous tumor formation, but in existing
tumors, it either exacerbates tumor formation or have no
eﬀect at all; (3) TZDs (Table 6, un-shaded rows), in most
cases, inhibits tumor formation with a rare exception of
Apc+/Min mice.
The activity of the Wnt/β-catenin signaling pathway
might account for these seemingly discrepant results, as
tumor models generated by APC mutation or polyoma
middle T antigen all involve overly active Wnt/β-catenin
signaling. TZDs are shown to induce β-catenin in colon
[55]. Paradoxically, reduction of PPARγ (Pparγ+/−) also
increasesβ-cateninexpressionincolon[57].Theappropriate
activation of PPARγ signaling might also be important.
Ligand-independent constitutive activation of PPARγ is
involved in the development of mammary gland tumors [60]
as well as in the action of PAX8-PPARγ in follicular thyroid
carcinoma [29].
5. CLINICAL TRIALS OF TZDs IN
HUMAN MALIGNANCIES
As discussed above, TZDs have been shown in many
preclinical studies to possess antitumor eﬀects that have
promptedseveralearly-phaseclinicalstudiestoevaluatetheir
eﬃcacies in various types of cancers. In this review, we
analyze these studies both in terms of clinical responses and
biological responses, focusing on recently published studies
that include more than 10 patients (Table 7).
AphaseIIclinicaltrialofrosiglitazonein12patientswith
liposarcoma was recently conducted. Eight of 12 patients
were fully evaluated for up to 16 months. As to clinical
response, all patients progressed while on treatment with
a mean time-to-progression of 5.5 months. Histological
appearance of repeated biopsy materials did not show any
signs of tumor diﬀerentiation. In one of the 8 patients,
PPARγ and fatty acid binding protein (FABP) were induced
after12-weekrosiglitazonetherapy,butdiseaseinthispatient
progressed similarly to the others [68]. Ten patients with
thyroid cancers were treated with rosiglitazone. Among
them, 4 had partial response, 2 had stable disease, and the
remaining 4 progressed. No correlation was found between
the clinical response and levels of PPARγ mRNA and protein
in these patients. PAX8-PPARγ status was not assessed
[69]. An early study evaluated eﬃcacy of troglitazone in
25 patients with metastatic colorectal carcinoma. All 25
patients progressed with a median time-to-progression of
1.6 months and a median survival time of 3.9 months
[70].
In breast cancer, data from two human trials have been
published. An early trial on 22 women with refractory breast
cancer showed no objective response to troglitazone in 18
of the 21 evaluable patients at 8 weeks after treatment. The
therapy was terminated in 16 patients due to progression
of their tumors. At 8 weeks, only three patients had
stable disease. All patients were evaluated for serum tumor
markers, CEA and CA27.29, which showed increased levels
within 8 weeks of treatment. Expression of PPARγ was not
determined in the study [71]. A short-term pilot trial of
rosiglitazone in 38 women with early stage breast cancer was
conducted. Clinical response was not assessed in this short-
term (<6 week) study. Biological response, as assessed by
Ki-67 staining on biopsy tissues before and after treatment,
was not detected in treated patients, either. Decreased
insulin levels and increased insulin sensitivity were noted
in these patients, suggesting that the rosiglitazone did aﬀect
metabolism as expected [72].
An early phase II trial of troglitazone in 41 patients with
metastatic prostate cancer showed a decrease in levels of
prostate-speciﬁc antigen (PSA) in 20% of patients enrolled10 PPAR Research
Table 7: Clinical trials of TZDs in cancer patients.
Cancer type Phase TZDs No. of pts Tumor response References
Liposarcoma II Rosiglitazone 12 All patients progressed, no sign of diﬀerentiation
by histology [68]
T h y r o i dc a n c e r I ,I I R o s i g l i t a z o n e 1 0 4 pts with partial response, 2 with stable disease,
and 4 with progressed disease [69]
Metastatic colorectal cancer I, II Troglitazone 25 All patients progressed [70]
Refractory breast cancer II Troglitazone 22 Most patients progressed with increased serum
tumor markers [71]
Early-stage breast cancer II Rosiglitazone 38 No reduction in Ki-67 staining on tissue biopsies [72]
Metastatic prostate cancer II Troglitazone 41 Decrease or stabilization of PSA [73]
Recurrent prostate cancer III Rosiglitazone 106 Similar to placebo in both PSADT and
time-to-disease-progression [74]
in the study. Prolonged stabilization of PSA was seen in 39%
of patients [73]. However, theseencouraging resultswerenot
reproduced in a large double-blind, randomized, placebo-
controlledtrialofrosiglitazonein106patientswithrecurrent
prostate cancer [74]. The time-to-disease-progression was
not signiﬁcantly diﬀerent between the rosiglitazone and
placebo groups. Moreover, the PSA doubling time, a pre-
dictor of clinical recurrence, was also not prolonged by the
treatment.
Taken together, TZDs appear to show little beneﬁt, both
in terms of clinical response and biological response, in
treating various types of human cancers despite promising
results from preclinical animal studies. It is worth noting
that most of the studies use low doses of TZDs which are
suﬃcient to activate PPARγ and control diabetes. It remains
possible that higher doses, even via receptor-independent
pathways, would be beneﬁcial for cancer patients. However,
one should keep in mind that TZDs are not a class of
drugs without dose-limiting toxicities. Troglitazone was
withdrawn from the market by the FDA in 2002 due to
liver toxicity. Most recently, increased cardiovascular risk has
been associated with rosiglitazone in the diabetic patient
population [75, 76] which has prompted the FDA to issue
label warnings.
6. TZDs AS CHEMOPREVENTIVE AGENTS IN
EPIDEMIOLOGY STUDIES
The clinical trials discussed above suggest that TZDs have
questionable eﬃcacy as chemotherapeutic agents in patients
who already have cancers. Do they have the potential to act
as chemopreventive agents? Recently, a large epidemiologic
study, involving a population of 87,678 veteran men with
diabetes, attempted to answer that question [77]. In this
retrospective study, incidence of lung, prostate, and colon
cancer in TZD users was compared to incidence in non-
TZD users and risk of cancer development was analyzed.
Only patients who obtained a cancer diagnosis after the date
of TZD initiation were included. TZD usage signiﬁcantly
reduced risk of lung cancer by 33%. It also reduced risk
of colon and prostate cancer, though without statistical
signiﬁcance. Interestingly, although the risk of prostate
cancer is not signiﬁcantly inﬂuenced by TZDs in the entire
population, when examining distinct populations, TZDs are
associated with an increased incidence of prostate cancer in
both Caucasians and African Americans. These data suggest
that the overall reduced risk is accounted for by the non-
Caucasian, non-African Americans populations in the study.
These data suggest that TZDs may be beneﬁcial for reducing
certain cancers in certain populations. Speciﬁc molecular
abnormalities in speciﬁc cancers and the genetic background
of diﬀerent populations may account for these apparently
diﬀerent results.
Although this study was quite strong, we suggest the fol-
lowing for future investigations: (1) separate TZD-users into
thoseusingrosiglitazoneandthoseusingpioglitazone. Inthe
cardiovascular risk studies, it was shown that rosiglitazone
increases the risk while pioglitazone decreases the risk [78].
(2) Evaluate the impact of the duration of TZD exposure on
risk of cancer development. (3) Determine the inﬂuence of
TZDs on the behavior of existing cancers.
7. CONCLUSIONS
In this article, we reviewed literature on the roles of
PPARγ in cancer with an emphasis on those that suggest a
proneoplastic function for the receptor. PPARγ, unlike MYC,
RAS, or p53, is neither a strong tumor promoter nor a tumor
suppressor. However, it may function as a “conditional
tumor promoter” or a “conditional tumor suppressor”
that modulates the tumorigenic process depending upon
cellular conditions, tumor types, or genetic background of
an animal strain or human individuals. TZDs, as a class
of pharmacological agent, may have receptor-independent
antineoplastic eﬀects, especially at doses higher than diabetic
doses or after long-term use and accumulation. It remains
possible that their antitumor activities would be enhanced
whenincombinationwithotherdrugs.Furtherinvestigation
is needed to address that possibility. To help clarify the roles
of PPARγ in cancer, future large epidemiological studies
of diabetic populations with concurrent cancers would be
helpful. In addition, investigations relating PPARγ activities
to the clinical outcomes of cancer patients would also be
informative.Y. Lynn Wang and Q. Miao 11
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